Clinical Trial Update: The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol

View source ↗

Summary

Marketing approval has been granted for eculizumab as a treatment for paroxysmal nocturnal hemoglobinuria under the sponsor's early access treatment protocol.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• SOLIRIS (eculizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Hemoglobinuria, Paroxysmal | Status: APPROVED_FOR_MARKETING